Evaxion to Present Two-Year Clinical Efficacy Data for AI-Designed Cancer Vaccine EVX-01 at ESMO Congress 2025

Evaxion will present two-year efficacy data from its AI-designed personalized cancer vaccine, EVX-01, at the ESMO Congress 2025. The phase 2 trial of EVX-01 combined with KEYTRUDA showed a 69% overall response rate in treating advanced melanoma. The presentation will occur in Berlin from October 17-21, 2025.

Evaxion A/S will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled from October 17-21, 2025, in Berlin, Germany. The presentation will highlight the company's AI-designed personalized cancer vaccine, EVX-01, which is being evaluated as a treatment for advanced melanoma.

The phase 2 trial, which combines EVX-01 with MSD's (Merck & Co., Inc.) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has shown promising results. Interim one-year data presented at the ESMO Congress in September 2024 demonstrated a 69% overall response rate and tumor reduction in 15 out of 16 patients. The trial has also shown a significant correlation (p=0.00013) between the AI-Immunology™ platform's predictions and actual immune responses to the vaccine's neoantigens [1].

The upcoming presentation of two-year efficacy data is particularly noteworthy because it provides critical insights into the durability of response, a key factor in cancer immunotherapy evaluation. For a personalized cancer vaccine, demonstrating sustained efficacy would represent a major advancement in the field of precision oncology.

The selection for presentation at ESMO, one of the world's premier oncology conferences, suggests the data is considered meaningful by expert reviewers. Additionally, the combination approach with KEYTRUDA® follows a rational therapeutic strategy of potentially enhancing T-cell responses against cancer through complementary mechanisms.

For Evaxion's business trajectory, this presentation offers an important opportunity to showcase their technology platform to potential partners, which could accelerate the clinical development process through strategic collaborations.

References:
[1] https://www.marketscreener.com/news/evaxion-a-s-to-present-two-year-clinical-efficacy-data-from-phase-2-trial-with-ai-designed-personal-ce7c5fdbdb80ff2c
[2] https://www.stocktitan.net/news/EVAX/evaxion-to-present-two-year-clinical-efficacy-data-from-phase-2-zto0etcvw0c7.html